Jeffrey S. Hackman - 15 Aug 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: FENC
Reported as of: 15 Aug 2024
Net transaction value: +$2,232,000
SEC form: 4
Accepted by SEC: 19 Aug 2024, 18:59:29 UTC
Prior SEC filing: 28 Sep 2023
Next SEC filing: 03 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Hackman

Key filing fact

Jeffrey S. Hackman filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 19 Aug 2024.

Key facts

This page summarizes Jeffrey S. Hackman's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Aug 2024, 18:59.

Change

Previous filing in this sequence was filed on 28 Sep 2023.
Current net transaction value: +$2,232,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FENC transaction Derivative

Stock Options

Award

Transaction value: $2,232,000
Shares: +400,000
Change %
Price: $5.58
Shares after: 400,000
Date: 15 Aug 2024
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 400,000
Exercise price: $5.58
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On August 15, 2024, Jeffrey Hackman was granted incentive stock options to purchase 400,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.

Footnote F2

One-third of the shares subject to this option may be exercised as of August 5, 2025 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of August 5, 2027, 100% of the total number of shares subject to this option shall be vested.